SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment reporting information
Revenues	$ 1,281	$ 1,196	$ 3,696	$ 3,511
Selling, general and administrative	528	511	1,670	1,550
Research and development	95	84	277	250
Operating income	95	43	1	75
Amortization of intangible assets	(68)	(72)	(202)	(220)
Other income (expense), net	15	(22)	(29)	(45)
Interest income	3	4	9	10
Interest expense	(101)	(100)	(323)	(301)
Loss on extinguishment of debt	3	0	(6)	0
Foreign exchange and other	(3)	(5)	(11)	(8)
Loss before provision for income taxes	(3)	(58)	(330)	(224)
Vision Care
Segment reporting information
Revenues	736	684	2,145	2,016
Pharmaceuticals
Segment reporting information
Revenues	330	306	906	883
Surgical
Segment reporting information
Revenues	215	206	645	612
Product sales
Segment reporting information
Revenues	1,277	1,192	3,682	3,499
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	509	464	1,513	1,369
Other revenues
Segment reporting information
Revenues	4	4	14	12
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	1	0	4	2
Operating Segment
Segment reporting information
Revenues	1,281	1,196	3,696	3,511
Operating income	301	283	729	799
Operating Segment \| Vision Care
Segment reporting information
Revenues	736	684	2,145	2,016
Selling, general and administrative	225	219	689	674
Research and development	15	12	34	36
Operating income	217	201	602	571
Operating Segment \| Pharmaceuticals
Segment reporting information
Revenues	330	306	906	883
Selling, general and administrative	132	137	439	385
Research and development	15	7	36	22
Operating income	76	69	124	200
Operating Segment \| Surgical
Segment reporting information
Revenues	215	206	645	612
Selling, general and administrative	72	64	218	195
Research and development	11	10	34	29
Operating income	8	13	3	28
Operating Segment \| Product sales
Segment reporting information
Revenues	1,277	1,192	3,682	3,499
Operating Segment \| Product sales \| Vision Care
Segment reporting information
Revenues	734	682	2,139	2,010
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	279	252	820	735
Operating Segment \| Product sales \| Pharmaceuticals
Segment reporting information
Revenues	329	305	902	881
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	106	93	303	274
Operating Segment \| Product sales \| Surgical
Segment reporting information
Revenues	214	205	641	608
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	124	119	390	360
Operating Segment \| Other revenues
Segment reporting information
Revenues	4	4	14	12
Operating Segment \| Other revenues \| Vision Care
Segment reporting information
Revenues	2	2	6	6
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	0	0	0	0
Operating Segment \| Other revenues \| Pharmaceuticals
Segment reporting information
Revenues	1	1	4	2
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	1	0	4	2
Operating Segment \| Other revenues \| Surgical
Segment reporting information
Revenues	1	1	4	4
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	0	0	0	0
Corporate
Segment reporting information
Operating income	$ (153)	$ (146)	$ (497)	$ (459)

Bausch & Lomb Corp 10-Q